Spero Accounts Payable from 2010 to 2024
| SPRO Stock | USD 1.30 0.03 2.26% |
Accounts Payable | First Reported 2015-12-31 | Previous Quarter 3.1 M | Current Value 2.7 M | Quarterly Volatility 1.9 M |
Check Spero Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Spero Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 4.1 M, Depreciation And Amortization of 684.9 K or Interest Expense of 0.0, as well as many indicators such as Price To Sales Ratio of 0.76, Dividend Yield of 0.0 or PTB Ratio of 0.69. Spero financial statements analysis is a perfect complement when working with Spero Therapeutics Valuation or Volatility modules.
Spero | Accounts Payable |
Latest Spero Therapeutics' Accounts Payable Growth Pattern
Below is the plot of the Accounts Payable of Spero Therapeutics over the last few years. An accounting item on the balance sheet that represents Spero Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Spero Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Spero Therapeutics' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Spero Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Accounts Payable | 10 Years Trend |
|
Accounts Payable |
| Timeline |
Spero Accounts Payable Regression Statistics
| Arithmetic Mean | 1,933,994 | |
| Geometric Mean | 1,722,357 | |
| Coefficient Of Variation | 52.12 | |
| Mean Deviation | 722,402 | |
| Median | 1,794,000 | |
| Standard Deviation | 1,008,006 | |
| Sample Variance | 1T | |
| Range | 3.5M | |
| R-Value | (0.11) | |
| Mean Square Error | 1.1T | |
| R-Squared | 0.01 | |
| Significance | 0.69 | |
| Slope | (25,024) | |
| Total Sum of Squares | 14.2T |
Spero Accounts Payable History
About Spero Therapeutics Financial Statements
Spero Therapeutics investors utilize fundamental indicators, such as Accounts Payable, to predict how Spero Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accounts Payable | 1.4 M | 1.6 M |
Pair Trading with Spero Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spero Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Spero Stock
The ability to find closely correlated positions to Spero Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spero Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spero Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spero Therapeutics to buy it.
The correlation of Spero Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spero Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spero Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spero Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Information and Resources on Investing in Spero Stock
When determining whether Spero Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spero Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spero Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spero Therapeutics Stock:Check out the analysis of Spero Therapeutics Correlation against competitors. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spero Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.753 | Earnings Share 0.34 | Revenue Per Share 2.223 | Quarterly Revenue Growth 2.754 | Return On Assets 0.1048 |
The market value of Spero Therapeutics is measured differently than its book value, which is the value of Spero that is recorded on the company's balance sheet. Investors also form their own opinion of Spero Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spero Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spero Therapeutics' market value can be influenced by many factors that don't directly affect Spero Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spero Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.